ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
면역치료제 시장 규모는 최근 빠르게 확대하고 있습니다. 2025년 3,104억 8,000만 달러에서 2026년에는 3,495억 3,000만 달러로, CAGR 12.6%로 성장할 것으로 예상됩니다. 지금까지의 성장은 면역치료의 선택지가 제한적이었던 점, 기존 암 치료에 대한 의존도, 암 및 자가면역질환의 발생률 증가, 단클론항체 관련 임상시험의 증가, 헬스케어 인프라의 확충 등이 요인으로 작용한 것으로 보입니다.
면역치료제 시장 규모는 향후 몇 년간 급속한 성장할 것으로 예상됩니다. 2030년에는 5,700억 달러에 달하고, CAGR은 13.0%를 기록할 전망입니다. 예측 기간의 성장 요인으로는 이중특이성항체 및 결합항체 개발, 맞춤형 면역치료 확대, 체크포인트 억제제 도입 증가, 치료용 백신 연구 투자 확대, 디지털 환자 모니터링과 AI 가이드형 면역치료의 통합 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 △단클론항체 및 체크포인트 억제제 도입 확대 △암 면역치료 및 자가면역질환 치료의 성장 △치료 및 예방백신 개발 증가 △T세포 수용체 및 사이토카인 기반 치료의 확대 △외래 및 입원 치료에서 면역치료의 통합 등이 있습니다. 등을 들 수 있습니다.
헬스케어 지출의 증가는 향후 몇 년 동안 면역치료제 시장의 성장을 견인할 것으로 예상됩니다. 헬스케어 지출은 특정 지역 또는 국가에서 일정 기간 동안 의료 제품 및 서비스에 대한 총 지출을 의미하며, 의사 진료, 입원, 수술, 진단 서비스, 치료와 관련된 비용을 포함합니다. 의료비 지출은 개인, 의료 제공자, 보험사, 정부 기관이 면역치료제 및 관련 치료의 비용으로 충당하고 있습니다. 예를 들어, 2024년 12월 미국 메디케어 및 메디케이드 서비스 센터(미국 메디케어 및 메디케이드 관리 기관)가 발표한 데이터에 따르면, 2023년 미국 헬스케어 지출은 전년 대비 7.5% 증가하여 4조 9,000억 달러(1인당 약 1만 4,570달러)에 달할 것으로 예상됩니다. 1 인당 약 1,570 달러)에 달할 것으로 예상됩니다. 그 결과, 의료비 지출 증가가 면역치료제 시장 확대에 기여하고 있습니다.
면역치료제 시장에서 활동하는 주요 기업들은 키트루다(펨브롤리주맙)와 같은 혁신적인 제품 개발에 집중하여 효과적이고 신뢰할 수 있는 치료 옵션을 제공하고 있습니다. 키트루다는 면역관문억제제로 분류되는 면역치료제로, 성인 환자를 위한 표적 치료제로 사용됩니다. 예를 들어, 2023년 1월 미국 제약사 머크는 식품의약국(FDA)의 승인을 받아 키트루다(펨브롤리주맙)를 출시했습니다. 키트루다는 면역체계를 활성화시켜 암세포를 인식하고 공격하게함으로써 여러 암종의 치료에 사용되며, 비소세포폐암(NSCLC)의 보조 치료제로 승인되었습니다. 이번 승인은 암 치료의 중요한 진전이며, 헬스케어 분야에 긍정적인 영향을 미칠 것으로 기대됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 시장에서 세계의 총 잠재 시장 규모(TAM)
제9장 시장 세분화
제10장 지역별, 국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자 환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업과 혁신적 기업
제38장 세계의 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
KSM
영문 목차
영문목차
Drugs for immunotherapy are medications designed to either stimulate or suppress the immune system to help the body defend itself against cancer, infections, and other diseases. Immunotherapy is a form of treatment that assists the immune system in recognizing and combating cancer, while also supporting the body's natural ability to fight infections and various disorders.
The primary types of drugs used in immunotherapy include monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and others. Monoclonal antibodies are produced by cloning a single white blood cell, with all resulting antibodies originating from one parent cell. These therapies are applied across areas such as cancer, autoimmune and inflammatory diseases, infectious diseases, and others, and are utilized in sectors including hospitals and clinics, ambulatory surgical centers, and others.
Tariffs have impacted the drugs for immunotherapy market by increasing costs for imported biologics, monoclonal antibodies, vaccines, and related reagents. Segments like monoclonal antibodies, checkpoint inhibitors, and therapeutic vaccines are most affected, with North America, Europe, and Asia-Pacific regions reliant on imports facing higher expenses and supply delays. However, tariffs have also encouraged domestic production, investment in local R&D, and development of cost-optimized immunotherapy solutions.
The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with a drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drugs for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The drugs for immunotherapy market size has grown rapidly in recent years. It will grow from $310.48 billion in 2025 to $349.53 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to limited immunotherapy options, reliance on conventional cancer treatments, growing incidence of cancer and autoimmune diseases, increasing clinical trials for monoclonal antibodies, rising healthcare infrastructure.
The drugs for immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $570 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to development of bispecific and conjugated antibodies, expansion of personalized immunotherapy, increasing adoption of checkpoint inhibitors, rising investments in therapeutic vaccine research, integration of digital patient monitoring and AI-guided immunotherapy. Major trends in the forecast period include rising adoption of monoclonal antibodies and checkpoint inhibitors, growth in cancer immunotherapy and autoimmune disease treatments, increasing development of therapeutic and preventive vaccines, expansion of t-cell receptor and cytokine-based therapies, integration of immunotherapy in ambulatory and hospital-based care.
The rising level of healthcare expenditure is expected to drive the growth of the drugs for immunotherapy market in the coming years. Healthcare expenditure represents the total spending on healthcare products and services within a specific region or country over a given period, including costs related to physician consultations, hospitalizations, surgical procedures, diagnostic services, and medical treatments. Financial resources for healthcare are provided by individuals, healthcare providers, insurance organizations, and government bodies to support the cost of immunotherapy drugs and related treatments. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering Medicare and Medicaid, healthcare spending in the United States increased by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. As a result, increasing healthcare expenditure is contributing to the expansion of the drugs for immunotherapy market.
Major companies operating in the drugs for immunotherapy market are concentrating on the development of innovative products, such as Keytruda (pembrolizumab), to deliver effective and reliable treatment options. Keytruda is an immunotherapy drug classified as an immune checkpoint inhibitor and is used as a targeted therapy for adult patients. For instance, in January 2023, Merck & Co., Inc., a US-based pharmaceutical company, launched Keytruda (pembrolizumab) following approval from the Food and Drug Administration. Keytruda is used to treat multiple types of cancer by activating the immune system to recognize and attack cancer cells and is approved as an adjuvant treatment for non-small cell lung cancer (NSCLC). This approval represents an important advancement in cancer therapy and is expected to positively influence the healthcare sector.
In December 2024, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer aims to strengthen its oncology portfolio by expanding into advanced immunotherapy approaches, particularly through Seagen's antibody-drug conjugate technologies for targeted cancer treatment. Seagen Inc. is a US-based biotechnology company specializing in the development and manufacturing of antibody-drug conjugates.
Major companies operating in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc., UbiVac, Bayer AG, Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies, Jounce Therapeutics Inc.
North America was the largest region in the immunotherapy market in 2025. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The drugs for immunotherapy market consist of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Drugs for Immunotherapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses drugs for immunotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for drugs for immunotherapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drugs for immunotherapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Type: Monoclonal Antibodies; Interferons; Interleukins; Vaccines; Checkpoint Inhibitors; Other Types
2) By Therapy Area: Cancer; Autoimmune & Inflammatory Diseases; Infectious Diseases; Other Therapy Areas
3) By End User: Hospitals & Clinics; Ambulatory Surgical Centers; Other End Users
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Rising Adoption Of Monoclonal Antibodies And Checkpoint Inhibitors
4.2.2 Growth In Cancer Immunotherapy And Autoimmune Disease Treatments
4.2.3 Increasing Development Of Therapeutic And Preventive Vaccines
4.2.4 Expansion Of T-Cell Receptor And Cytokine-Based Therapies
4.2.5 Integration Of Immunotherapy In Ambulatory And Hospital-Based Care
5. Drugs for Immunotherapy Market Analysis Of End Use Industries
5.1 Hospitals & Clinics
5.2 Ambulatory Surgical Centers
5.3 Oncology Centers
5.4 Research Laboratories
5.5 Pharmaceutical Companies
6. Drugs for Immunotherapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Drugs for Immunotherapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Drugs for Immunotherapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Drugs for Immunotherapy Market Size, Comparisons And Growth Rate Analysis
7.3. Global Drugs for Immunotherapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Drugs for Immunotherapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Drugs for Immunotherapy Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Drugs for Immunotherapy Market Segmentation
9.1. Global Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types
9.2. Global Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas
9.3. Global Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users
9.4. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.7. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Preventive Vaccines, Therapeutic Vaccines
9.8. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Checkpoint Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.9. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Cancer Cell Therapies, Cytokine Therapy, T-Cell Receptor Therapy
10. Drugs for Immunotherapy Market Regional And Country Analysis
10.1. Global Drugs for Immunotherapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Drugs for Immunotherapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Drugs for Immunotherapy Market
11.1. Asia-Pacific Drugs for Immunotherapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Drugs for Immunotherapy Market
12.1. China Drugs for Immunotherapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Drugs for Immunotherapy Market
13.1. India Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Drugs for Immunotherapy Market
14.1. Japan Drugs for Immunotherapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Drugs for Immunotherapy Market
15.1. Australia Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Drugs for Immunotherapy Market
16.1. Indonesia Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Drugs for Immunotherapy Market
17.1. South Korea Drugs for Immunotherapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Drugs for Immunotherapy Market
18.1. Taiwan Drugs for Immunotherapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Drugs for Immunotherapy Market
19.1. South East Asia Drugs for Immunotherapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Drugs for Immunotherapy Market
20.1. Western Europe Drugs for Immunotherapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Drugs for Immunotherapy Market
21.1. UK Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Drugs for Immunotherapy Market
22.1. Germany Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Drugs for Immunotherapy Market
23.1. France Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Drugs for Immunotherapy Market
24.1. Italy Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Drugs for Immunotherapy Market
25.1. Spain Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Drugs for Immunotherapy Market
26.1. Eastern Europe Drugs for Immunotherapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Drugs for Immunotherapy Market
27.1. Russia Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Drugs for Immunotherapy Market
28.1. North America Drugs for Immunotherapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Drugs for Immunotherapy Market
29.1. USA Drugs for Immunotherapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Drugs for Immunotherapy Market
30.1. Canada Drugs for Immunotherapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Drugs for Immunotherapy Market
31.1. South America Drugs for Immunotherapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Drugs for Immunotherapy Market
32.1. Brazil Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Drugs for Immunotherapy Market
33.1. Middle East Drugs for Immunotherapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Drugs for Immunotherapy Market
34.1. Africa Drugs for Immunotherapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Drugs for Immunotherapy Market Regulatory and Investment Landscape
36. Drugs for Immunotherapy Market Competitive Landscape And Company Profiles
36.1. Drugs for Immunotherapy Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Drugs for Immunotherapy Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Drugs for Immunotherapy Market Company Profiles
36.3.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.4. UbiVac Overview, Products and Services, Strategy and Financial Analysis
36.3.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
37. Drugs for Immunotherapy Market Other Major And Innovative Companies
